YOU CAN MAKE A DIFFERENCE!
Help Impact the FDA’s Decision to Improve Glucose Control in People with Type 1 Diabetes Who are Also Living with Chronic Kidney Disease with an Oral Medication
(No monetary contribution is required to sign this petition and any financial contributions given via change.org do not go to TCOYD.)
If you or a loved one are living with type 1 diabetes then you know the literal blood, sweat, and tears that go into managing this 24-hour 365-days-a-year condition. Did you know that the FDA is considering approving the first oral medication for type 1s living with chronic kidney disease to improve glucose control?
Sotagliflozin is a once daily oral medication that is currently approved by the FDA only in people with type 2 diabetes to improve glycemic control and reduce the risk of a stroke, heart attack, hospitalization, or death from congestive heart failure. Importantly, it is used in people with type 2 diabetes to reduce the progression of chronic kidney disease.
If approved, sotagliflozin would be the first oral medication approved for those living with type 1 diabetes since the discovery of insulin over 100 years ago.
(No monetary contribution is required to sign this petition and any financial contributions given via change.org do not go to TCOYD.)
We call upon the U.S. Food and Drug Administration (FDA) to address the need for new therapeutic options for people with Type 1 diabetes (T1D) who are also living with CKD.
People with type 1 diabetes face significantly higher risks of morbidity and mortality. In the United States, an estimated 1.7 million adults have type 1 diabetes, with approximately 21%, or 360,000, also affected by CKD. This petition represents the voices of T1D patients, families, healthcare providers, and advocates who are eager for innovative and effective options to manage this life-altering condition.